# Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

> **NCT06724809** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 21 (actual)

## Conditions studied

- NMOSD
- Neuromyelitis Optica Spectrum Disorders

## Interventions

- **DRUG:** eculizumab

## Key facts

- **NCT ID:** NCT06724809
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2026-12-07
- **Final completion:** 2026-12-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06724809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06724809, "Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06724809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*